MX2018004256A - Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. - Google Patents

Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.

Info

Publication number
MX2018004256A
MX2018004256A MX2018004256A MX2018004256A MX2018004256A MX 2018004256 A MX2018004256 A MX 2018004256A MX 2018004256 A MX2018004256 A MX 2018004256A MX 2018004256 A MX2018004256 A MX 2018004256A MX 2018004256 A MX2018004256 A MX 2018004256A
Authority
MX
Mexico
Prior art keywords
compounds
nr2b antagonists
selective nr2b
selective
antagonists
Prior art date
Application number
MX2018004256A
Other languages
English (en)
Inventor
Islam Imadul
Thangathirupathy Srinivasan
Sankara Warrier Jayakumar
Cheruku Srinivas
Shetty Poornima
Venkat Ram Krishna Mohan GUPTA Grandhi
E Macor John
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2018004256A publication Critical patent/MX2018004256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La descripción generalmente se refiere a compuestos de fórmula I, que incluyen sus sales, así como a composiciones y métodos de uso de los compuestos. Los compuestos son ligandos del receptor NR2B y pueden ser útiles para el tratamiento de diversos trastornos del sistema nervioso central.
MX2018004256A 2015-10-14 2016-10-13 Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. MX2018004256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3308DE2015 2015-10-14
PCT/US2016/056714 WO2017066366A1 (en) 2015-10-14 2016-10-13 Selective nr2b antagonists

Publications (1)

Publication Number Publication Date
MX2018004256A true MX2018004256A (es) 2018-05-16

Family

ID=57223768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004256A MX2018004256A (es) 2015-10-14 2016-10-13 Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.

Country Status (13)

Country Link
US (2) US10344020B2 (es)
EP (1) EP3362441B1 (es)
JP (1) JP6938485B2 (es)
KR (1) KR20180063306A (es)
CN (1) CN108137543B (es)
AU (1) AU2016340237A1 (es)
BR (1) BR112018006537A2 (es)
CA (1) CA3001890A1 (es)
EA (1) EA201890946A1 (es)
ES (1) ES2818254T3 (es)
IL (1) IL258603A (es)
MX (1) MX2018004256A (es)
WO (1) WO2017066366A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023006567A (es) * 2020-12-04 2023-06-16 Novartis Ag Regimen de dosificacion para un nam del receptor nr2b-nmda para el tratamiento de la depresion.
US11646085B2 (en) 2021-06-17 2023-05-09 Sandisk Technologies Llc Toggle mode frequency optimization by dynamic ODT matching for non-volatile memory
CN116354923B (zh) * 2021-12-27 2025-05-09 江苏恩华药业股份有限公司 一种含氮杂环化合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960589B2 (en) 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
DE602004015610D1 (de) 2003-06-04 2008-09-18 Merck & Co Inc 3-fluoro-piperidine als nmda/nr2b antagonisten
EP2520567A3 (en) * 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
JP2009067784A (ja) * 2007-08-21 2009-04-02 Shionogi & Co Ltd 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤
EP2163541A1 (en) 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
CN105037492A (zh) 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
EP3087067B1 (en) * 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
ES2822830T3 (es) * 2015-10-14 2021-05-05 Bristol Myers Squibb Co Antagonistas selectivos de NR2B

Also Published As

Publication number Publication date
EP3362441A1 (en) 2018-08-22
CA3001890A1 (en) 2017-04-20
ES2818254T3 (es) 2021-04-09
WO2017066366A1 (en) 2017-04-20
KR20180063306A (ko) 2018-06-11
JP2018536637A (ja) 2018-12-13
CN108137543B (zh) 2021-11-23
CN108137543A (zh) 2018-06-08
JP6938485B2 (ja) 2021-09-22
US20180312491A1 (en) 2018-11-01
US10961229B2 (en) 2021-03-30
IL258603A (en) 2018-06-28
EP3362441B1 (en) 2020-08-12
BR112018006537A2 (pt) 2018-10-16
EA201890946A1 (ru) 2018-09-28
AU2016340237A1 (en) 2018-05-31
US20200071304A1 (en) 2020-03-05
US10344020B2 (en) 2019-07-09

Similar Documents

Publication Publication Date Title
TW201613884A (en) Selective NR2B antagonists
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2021014128A (es) Polimorfos de selinexor.
NZ737399A (en) Ccr2 modulators
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
EA201691442A1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
PH12017500089A1 (en) Aldosterone synthase inhibitors
PH12016502347A1 (en) 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
EA201890764A1 (ru) Селективные антагонисты nr2b
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
TW201612169A (en) (R)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
WO2013048949A3 (en) Selective nr2b antagonists
MX360001B (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
IN2013CH01199A (es)